The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years.
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...